


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)
 Stock code: 2120

VOLUNTARY ANNOUNCEMENT
PRINCIPAL OPERATING DATA AND INDICATORS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
AND THE THIRD QUARTER 2026

This is a voluntary announcement made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The table below sets forth the relevant operating data and indicators of the Group’s owned hospitals by inpatients and outpatients for the nine months ended September 30, 2026 with comparative figures for the nine months ended September 30, 2025:

	For the nine months ended September 30,		
	2026	2025	Year-on-year changes
Inpatients			
Number of inpatient bed-days	2,823,695	2,830,593	-0.2%
Average inpatient spending per bed-day on treatment and general healthcare services (RMB)	288	290	-0.7%
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	45	47	-4.3%
Total average inpatient spending per bed-day (RMB)⁽¹⁾	333	337	-1.2%

	For the nine months ended September 30,		
	2026	2025	Year-on-year changes
Outpatients			
Number of outpatient visits	438,875	519,213	-15.5%
Average outpatient spending per visit on treatment and general healthcare services (RMB)	82	78	5.1%
Average outpatient spending per visit on pharmaceutical sales (RMB)	216	199	8.5%
Total average outpatient spending per visit (RMB)	298	277	7.6%

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the three months (the third quarter) from July 1, 2026 to September 30, 2026 with comparative figures of the same period in 2025:

	Three months from July 1 to September 30,		
	2026	2025	Year-on-year changes
Inpatients			
Number of inpatient bed-days	960,524	989,008	-2.9%
Average inpatient spending per bed-day on treatment and general healthcare services (RMB)	290	286	1.4%
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	44	47	-6.4%
Total average inpatient spending per bed-day (RMB)⁽¹⁾	334	333	0.3%

	Three months from July 1 to September 30,		
	2026	2025	Year-on-year changes
Outpatients			
Number of outpatient visits	142,692	177,477	-19.6%
Average outpatient spending per visit on treatment and general healthcare services (RMB)	89	81	9.9%
Average outpatient spending per visit on pharmaceutical sales (RMB)	214	195	9.7%
Total average outpatient spending per visit (RMB)	303	276	9.8%

Note:

1. The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data and indicators may be different from those disclosed in relevant periodical reports. The operating data and indicators disclosed in relevant periodical reports shall prevail if there is any discrepancy.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
October 6, 2026

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao, Mr. LI Changhao and Mr. XU Yongjiu; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. SZETO Wing Fu.